The Need for Biomarkers in the ALS–FTD Spectrum: A Clinical Point of View on the Role of Proteomics

Keyphrases

• Proteomics 100%
• Neurodegenerative Diseases 50%
• Amyotrophic Lateral Sclerosis 50%
• Frontotemporal Dementia 50%
• Protein Inclusions 50%
• Clinical Practice 25%
• Protein Expression 25%
• Neuronal Loss 25%
• Neuronal Damage 25%
• Protein Function 25%
• Pathological Features 25%
• Cerebrospinal Fluid 25%
• Protein Modification 25%
• Biological Fluids 25%
• Tissue Fluid 25%
• Protein Profiling 25%
• Neuronal Cells 25%
• Biological Processes 25%
• Protein Structure 25%
• Disease-modifying Therapy 25%
• Plasma Fluid 25%
• Cellular Dysfunction 25%
• Structure Interaction 25%
• Structure Modification 25%
• Disease-related Proteins 25%
• Personalized Medicine 25%
• Narrative Review 25%
• New Drug Development 25%
• Protein Alteration 25%
• Spectrum Disorder 25%

Medicine and Dentistry

• Biological Marker 100%
• Proteomics 100%
• Amyotrophic Lateral Sclerosis 50%
• Frontotemporal Lobar Degeneration 50%
• Diseases 50%
• Neurodegenerative Disorder 25%
• Clinician 25%
• Cerebrospinal Fluid 25%
• Biological Phenomena and Functions Concerning the Entire Organism 25%
• Personalized Medicine 25%
• Degenerative Disease 25%
• Spectrum Disorder 25%

Biochemistry, Genetics and Molecular Biology

• Proteomics 100%
• Biological Phenomena and Functions Concerning the Entire Organism 25%
• Blood Plasma 25%
• Drug Development 25%